ClinicalTrials.gg
RecruitingNCT04102566Updated Sep 27, 2019

Optimizing Pain Control in Transurethral Resection of the Prostate

A Phase 4 interventional study of Ibuprofen 600 mg and Education in Pain, BPH With Urinary Obstruction and BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms, sponsored by Benaroya Research Institute. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-27.

Sponsored by Benaroya Research Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2019, 7 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 1 year 9 months after the study started (first participant enrolled Dec 2017, registered Sep 2019).
  • Started Dec 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Planned enrollment
62nd of 86
50 · median 100
Started
2017
with 7 others
Phase 4
30 of 86
3 open now
Registered
68th of 86
by date

Among the 86 studies testing ibuprofen in Pain, this one is the 62nd largest by planned enrollment, is one of 8 that started in 2017, is one of 30 in phase 4, and was the 68th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to develop a multi-modal protocol for pain management after TURP that minimizes opioid use. The investigators hypothesize this approach will provide non-inferior pain control to the current standard of care which includes opioids as the primary agent. The investigators believe this is an important step in reducing the opioid epidemic in surgical patients.

Read the detailed description

In our study, the investigators will randomize TURP patients to standard of care versus a multi-modal protocol. Multi-modal pain control is defined as: "analgesia that combines 2 or more agents that act by different mechanisms to provide analgesia with better pain relief and less opioids". In addition, patients in the intervention arm will receive education regarding pain control and opioid use. The investigators aim to demonstrate non-inferior pain control with this approach. The investigators hope this will inform new guidelines for pain control after TURP, minimize opioid use in this patient population, and educate physicians and patients on providing excellent pain control while minimizing the risks of opioid use. The investigators believe this could ultimately serve as a model for other endoscopic urologic procedures as well.

03

Conditions studied

  • Pain
  • BPH With Urinary Obstruction
  • BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms

Keywords

  • postoperative pain
  • Transurethral resection of the prostate
  • Multimodal pain control
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are identified as candidates for TURP
  • Are 18 years of age or greater
  • Are proficient in English

Exclusion criteria

Exclusion Criteria:

  • Have filled an opioid prescription in the last 2 months
  • Have an allergy to a medication included in the protocol
  • Have a history of pelvic radiation
  • Have renal failure (Serum Cr > 2.0 mg/dl), peptic ulcer disease, history of gastric bypass, cirrhosis, or other precluding use of NSAID's
  • Have liver failure, hepatitis, or alcohol abuse which precludes use of acetaminophen
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • No intervention
    Standard of care arm

    The standard of care group will group will receive the following regimen while inpatient: * 2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours * Acetaminophen 1000mg every 8 hours standing * Oxycodone 5mg PO every 4 hours as needed pain * Phenazopyridine 100mg TID as needed for urinary burning * Senna 1 tab every 12 hours * Miralax 17g powder once daily as needed for constipation The standard of care group will get the following prescriptions on discharge: * Oxycodone 5mg every 4 hours as needed pain - 15 tabs * Acetaminophen 1000mg every 8 hours standing for two days then as needed * Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs * Senna 1 tab every 12 hours - 10 tabs

  • Experimental
    Multi-modal group

    The multi-modal group will receive the following regimen while inpatient: * 2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours * Acetaminophen 1000mg every 8 hours standing * Ibuprofen 600mg every 6 hours standing * Oxycodone 5mg PO every 4 hours as needed pain * Phenazopyridine 100mg TID as needed for urinary burning * Senna 1 tab every 12 hours * Miralax 17g powder once daily as needed for constipation * Patient Education (Figures 2 \& 3) The multi-modal group will receive the following prescriptions on discharge: * Acetaminophen 1000mg every 8 hours standing for two days then as needed - 30 tabs * Ibuprofen 600mg every 8 hours standing for two days then as needed - 30 tabs * Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs * Senna 1 tab every 12 hours - 10 tabs

    Drug: Ibuprofen 600 mg · Behavioral: Education

Interventions

  • DrugIbuprofenStudies of IbuprofenIbuprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.

  • BehavioralEducation

    We'll be adding education to patient's post-operative instructions to aid in their pain control management.

06

What researchers measure

Primary outcomes

  1. Opioid Consumption

    Total opioid utilization

    Time frame: PACU-72 hours

  2. Pain Scores

    Numerical Rating Scale Pain Scores (Range: 0-10, where 0 is no pain and 10 is the worst pain)

    Time frame: PACU-72 hours

Secondary outcomes

  1. Presence of a foley catheter at discharge.

    Was the patient discharged with a Foley catheter?

    Time frame: 0-48hours

  2. Presence of narcotic side effects

    nausea/vomiting, pruritus, constipation, dizziness or feelings of sedation

    Time frame: 48 hours after discharge

  3. Were there any post-operative complications

    Any complications post-operatively that occurred in the immediate post-operative setting.

    Time frame: 0-48 hours

07

Study locations

1 of 1 sites recruiting
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
    Recruiting
    • Ryan Donahue, MD · Contactryan.donahue@vmmc.org · 512-484-3214
    • Una Lee, MD · Contactuna.lee@vmmc.org · 2062236749
    • Kathleen Kobashi, MD · Sub investigator
    • Alvaro Lucioni, MD · Sub investigator
    • Fred Govier, MD · Sub investigator
    • Christopher Porter, MD · Sub investigator
    • John Corman, MD · Sub investigator
    • Thomas Pritchett, MD · Sub investigator
    • Christopher Kuhr, MD · Sub investigator
    • Dena Moskowitz, MD · Sub investigator
    • Neil Hanson, MD · Sub investigator
    • Andrew Stamm, MD · Sub investigator
    • Ryan Donahue, MD · Sub investigator
    • Una Lee, MD · Principal investigator
08

References and documents

Publications

  • Alam A, Gomes T, Zheng H, Mamdani MM, Juurlink DN, Bell CM. Long-term analgesic use after low-risk surgery: a retrospective cohort study. Arch Intern Med. 2012 Mar 12;172(5):425-30. doi: 10.1001/archinternmed.2011.1827. PubMed 22412106 ↗
  • Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period. JAMA Intern Med. 2016 Sep 1;176(9):1286-93. doi: 10.1001/jamainternmed.2016.3298. Erratum In: JAMA Intern Med. 2016 Sep 1;176(9):1412. doi: 10.1001/jamainternmed.2016.5221. JAMA Intern Med. 2022 Jun 1;182(6):690. doi: 10.1001/jamainternmed.2022.0812. JAMA Intern Med. 2022 Jul 1;182(7):783. doi: 10.1001/jamainternmed.2022.1632. PubMed 27400458 ↗
  • Hill MV, Stucke RS, McMahon ML, Beeman JL, Barth RJ Jr. An Educational Intervention Decreases Opioid Prescribing After General Surgical Operations. Ann Surg. 2018 Mar;267(3):468-472. doi: 10.1097/SLA.0000000000002198. PubMed 28267689 ↗
  • Hill MV, McMahon ML, Stucke RS, Barth RJ Jr. Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures. Ann Surg. 2017 Apr;265(4):709-714. doi: 10.1097/SLA.0000000000001993. PubMed 27631771 ↗
  • Kose O, Saglam HS, Altun ME, Sonbahar T, Kumsar S, Adsan O. Prilocaine irrigation for pain relief after transurethral resection of the prostate. J Endourol. 2013 Jul;27(7):892-5. doi: 10.1089/end.2013.0001. Epub 2013 Jun 12. PubMed 23565930 ↗
  • American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012 Feb;116(2):248-73. doi: 10.1097/ALN.0b013e31823c1030. No abstract available. PubMed 22227789 ↗
  • Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016 Apr 19;315(15):1624-45. doi: 10.1001/jama.2016.1464. PubMed 26977696 ↗
  • Maughan BC, Hersh EV, Shofer FS, Wanner KJ, Archer E, Carrasco LR, Rhodes KV. Unused opioid analgesics and drug disposal following outpatient dental surgery: A randomized controlled trial. Drug Alcohol Depend. 2016 Nov 1;168:328-334. doi: 10.1016/j.drugalcdep.2016.08.016. Epub 2016 Sep 20. PubMed 27663358 ↗

Individual participant data

Plan to share: No — IPD will not be shared with other researchers. IPD will be used solely for this study cohort and protocol.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Oct 2019, 21 months after the start.

Of 280 non-industry phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 21 months is above that.

Counting every sponsor, half of 295 studies reached it within 18 months; a quarter within 8 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 25, 2019
StartActual
Dec 8, 2017
Primary completionEst.
Oct 1, 2019
CompletionEst.
Dec 1, 2019
Last update
Sep 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04102566
Lead sponsor
Benaroya Research Institute
Collaborators
Virginia Mason Hospital/Medical Center
Responsible party
Una Lee (Principal Investigator and Attending urologist, Benaroya Research Institute) — Principal investigator
First posted
Sep 25, 2019
Start date
Dec 8, 2017
Primary completion
Oct 1, 2019 (estimated)
Completion
Dec 1, 2019 (estimated)
Last update
Sep 27, 2019

Study contacts

Ryan Donahue, MD
Contact
ryan.donahue@vmmc.org
2062236600

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion